EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series

Fredrik N Albach, Elpida Phithak, Robert Biesen, Arnd Kleyer, Elise Siegert, Ioanna Minopoulou, Engi Algharably, Vincent Casteleyn, Anne E Beenken, Udo Schneider, Sofia Trezzini, Marie Rehm und 25 weitere

Annals of the Rheumatic Diseases · 2026-06

DOI: 10.1016/j.ard.2026.05.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-06. Verfasst von Fredrik N Albach und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Fraunhofer Institute for Translational Med…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, Else Kröner Fresenius Foundation, Horizon 2020 Framework Programme.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to evaluate the safety and efficacy of teclistamab, a T cell-redirecting bispecific antibody targeting B-cell maturation antigen, in a case series of severe autoimmune diseases. METHODS: Data were retrospectively collected from patients with treatment-refractory systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), systemic lupus erythematosus (SLE), undifferentiated connective tissue disease (UCTD), or IgG4-related disease (IgG4-RD) who received 1 cycle of teclistamab at 5 European centres. RESULTS: Eighteen patients (72% women, median age 48.5 years, 10 SSc, 4 IIM, 2 SLE, 1 UCTD, and 1 IgG4-RD) with a median of 5 prior therapies and a median cumulative dose of 6.36 mg/kg teclistamab were included. The median follow-up was 5.1 months (range, 0.8-21.2 months). A total of 22 cytokine release syndrome episodes (16 grade 1 and 6 grade 2) occurred in 12 patients (67%). All patients developed severe hypogammaglobulinaemia, and 5 (28%) experienced severe infections. Two patients developed an inflammatory bowel disease-like colitis. Two patients with severe SSc-associated cardiac involvement died, 1 due to sudden cardiac death and the other following diffuse alveolar haemorrhage and heart failure. B-cell depletion was observed in all patients, accompanied by significant reductions in autoantibody levels. Teclistamab was associated with major clinical responses in 11 (61%) and minimal-to-moderate responses in 4 (22%) patients, despite discontinuation of immunosuppressive therapy. CONCLUSIONS: Teclistamab demonstrated the potential to induce treatment-free responses in refractory autoimmune disease, but clinically relevant safety events, including infections and fatal outcomes in patients with advanced cardiac involvement, highlight the need for careful patient selection and monitoring.

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, c/o Charité - Univ…
  • Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany.
  • Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Rheumatology and Clinical Immunology, Immanuel Krankenhaus, Berlin, Germany.
  • Faculty of Medicine and Dentistry, University La Sapienza, Rome, Italy.

Förderung

  • Horizon 2020
  • Else Kröner Fresenius Foundation
  • Horizon 2020 Framework Programme

Zitieren

APA

Albach, F. N., Phithak, E., Biesen, R., Kleyer, A., Siegert, E., Minopoulou, I., Algharably, E., Casteleyn, V., Beenken, A. E., Schneider, U., Trezzini, S., Rehm, M., Sattler, A., Sinzinger, B., Wiebe, E., Unterwalder, N., Scholz, V., Staeck, A., Hütter-Krönke, M. L., …, & Alexander, T. (2026). Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.05.021

Vancouver

Albach FN, Phithak E, Biesen R, Kleyer A, Siegert E, Minopoulou I, et al. Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.05.021

BibTeX
@article{Albach2026,
  author = {Albach, Fredrik N and Phithak, Elpida and Biesen, Robert and Kleyer, Arnd and Siegert, Elise and Minopoulou, Ioanna and Algharably, Engi and Casteleyn, Vincent and Beenken, Anne E and Schneider, Udo and Trezzini, Sofia and Rehm, Marie and Sattler, Arne and Sinzinger, Benedikt and Wiebe, Edgar and Unterwalder, Nadine and Scholz, Veronika and Staeck, Anja and Hütter-Krönke, Marie Luise and Buttgereit, Frank and Keller, Ulrich and Busse, Antonia and Krönke, Jan and Kötter, Ina and Kremer, Phillip and Exner, Tarik and Pecher, Ann-Christin and Kaudewitz, Dorothee and Sondergaard, Klaus and Troldborg, Anne and Henes, Jörg and Lorenz, Hanns-Martin and Haase, Isabell and Krusche, Martin and Krönke, Gerhard and Simon, David and Alexander, Tobias},
  title = {Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2026.05.021}
}
Kostenlos starten →